In the case of hormone therapy, the presence of hormone receptors in tumor cells correlates with the benefit of hormone therapy, which uses substances that inhibit the activity of endogenous hormones progesterone and estrogen in the breast.21In agreement with these data, in the present study, the highest frequency of hormone therapy was between the subtypes luminal A and luminal B-HER2 negative, tumors that have hormone receptors. Here, ERBB2 is linked to neoplasm.